Clinical trial NCT00790595 - References

Prostate Cancer — Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

Citation(s)

•   Bagshaw MA, Cox RS, Ramback JE
  Radiation therapy for localized prostate cancer. Justification by long-term follow-up. Urol Clin North Am. 1990 Nov;17(4):787-802.
•   Cancer Facts and Figures 2004
  American Cancer Society, 2004.
•   Catalona WJ, Bigg SW
  Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol. 1990 Mar;143(3):538-43; discussion 544.
•   Cumming JA, Ritchie AW, Goodman CM, McIntyre MA, Chisholm GD
  De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease. Br J Urol. 1990 Mar;65(3):271-4.
•   Frazier HA, Robertson JE, Humphrey PA, Paulson DF
  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 1993 Mar;149(3):516-8.
•   Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA
  Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol. 1989 Aug;142(2 Pt 1):326-31.
•   Kasamon KM, Dawson NA
  Update on hormone-refractory prostate cancer. Curr Opin Urol. 2004 May;14(3):185-93. Review.
•   Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC
  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May 5;281(17):1591-7.
•   R Motzer, B Rini, M Michaelson, B Redman, G Hudes, G Wilding, R Bukowski, D George, S Kim, I Chen, C Baum and the SU11248 Study Group: Phase 2 Trials of SU11248 Show Antitumor Activity in Second-Line Therapy for Patients with Metastatic Renal Cell Carcinoma (RCC)
  ASCO, 2005.
•   Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ
  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004 Sep;172(3):910-4.
•   Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT
  Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol. 1992 Aug;148(2 Pt 1):331-7.
•   Stamey TA and McNeal JE: Adenocarcinoma of the prostate
  In Campbell's Urology 6th edition (Walsh PC, Retik AB, Stamey MA and Vaughan ED, eds), W.B. Saunders Co., pp 1159-1221, 1992.
•   Stamey TA, Kabalin JN, Ferrari M
  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol. 1989 May;141(5):1084-7.
•   Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS
  Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol. 1990 Jun;143(6):1166-72; discussion 1172-3.
•   Stein A, deKernion JB, Dorey F
  Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. Br J Urol. 1991 Jun;67(6):626-31.
•   Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK
  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. Review. Erratum in: J Natl Cancer Inst. 2003 Nov 5;95(21):1641.
•   Wheeler JA, Zagars GK, Ayala AG
  Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer. 1993 Jun 1;71(11):3783-7.
•   Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ
  Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer. 1987 Oct 1;60(7):1489-99.
•   Zagars GK
  Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23(1):47-53.

Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

Details for clinical trial NCT00790595